The FY23 Defense Appropriations Act provides funding for the Bone Marrow Failure Research Program to support innovative, high-impact bone marrow failure research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.
